Medical Device

Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function Medtronic plc the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration for the Emprint™ ablation catheter kit an investigational device not yet approved or cleared in the United States . The ...

Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the Emprint™ ablation catheter kit an investigational device not yet approved or cleared in the United States . The catheter is intended to be used in conjunction with the Emprint™ microwave generator and Medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung, and it can be used together with standard of care therapy when indicated.

The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Under the program, the FDA will provide Medtronic with priority review and interactive communication regarding clinical trial designs through to commercialization decisions.

Current clinical guidelines for the management of malignant lung lesions support a multimodal approach, which may include surgery, radiotherapy, and/or systemic drug therapy depending on the tumor stage. Because patients with lung malignancies have been shown to have survival benefit from a combination of systemic and local therapy, less invasive local treatment modalities such as the Emprint ablation catheter kit have been developed. 1 Using an endoluminal approach, the Emprint ablation catheter kit will be studied with the Medtronic lung navigation system to allow for accurate delivery of microwave energy to the targeted lung lesion(s). Clinical guidelines recommend incorporating local therapies such as thermal ablation, in combination with systemic therapies when suitable.

Though not yet available in the United States , the Emprint ablation catheter kit is CE Marked and the NAVABLATE study completed enrollment of 30 subjects in Europe and Hong Kong in 2020.

"This new technology has allowed me to personalize treatment of lung lesions for each patient, particularly lesions that may be challenging to manage," said Mr. Kelvin Lau, MA, DPhil, FRCS(CTh), a consultant thoracic surgeon at St. Bartholomew's Hospital, London , and principal investigator for the NAVABLATE study.

The Medtronic lung navigation platform enables precise and accurate placement of the ablation catheter within the target lesion, which is critical for the success of this minimally invasive procedure. 2 With 15 years of experience, the navigation platform has been used in more than 200,000 lung procedures.

"At Medtronic, we strive to transform outcomes by taking bold actions to ensure that patients with tumors in the lung receive care sooner, less invasively, and more effectively," said Emily Elswick , vice president and general manager, Lung Health & Visualization, within the Surgical Innovations business, which is part of the Medical Surgical Portfolio at Medtronic. "Breakthrough designation from the FDA is just the first-step in realizing our broader commitment to providing less invasive treatment options to patients with lung disease."

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.




1 Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. (CAN BE "et al."); JAMA Netw Open. 2019 Aug 2;2(8):e199702. doi: 10.1001/jamanetworkopen.2019.9702.

2 Bhadra K, MattingleyJ, Pritchett M. Electromagnetic navigation bronchoscopy with advanced fluoroscopy-based localization and intraprocedural local registration for the evaluation of peripheral pulmonary nodules. Paper presented at: CHEST Annual Meeting; October 23, 2019; New Orleans, LA.

Contacts:




Kira Jastive

Ryan Weispfenning

Public Relations

Investor Relations

+1-508-452-4238

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/medtronic-receives-fda-breakthrough-designation-for-the-emprint-ablation-catheter-kit-301277288.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

  • New partnership will provide physician training to drive improved diversity in clinical trials
  • Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists
  • Provides opportunities for underrepresented physicians to receive training on the clinical trials process, learn new skills, expand their networks and increase visibility with industry partners

Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.

Women as One is a nonprofit organization with the mission to promote talent in medicine by providing women physicians with unique professional opportunities. Abbott provided funding to develop a new program called CLIMB Research, which provides skills training for underrepresented cardiologists.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

The Company has also appointed Paul Ruh as CFO Designate

Mongon and Ruh to Assume New Leadership Roles Upon the Completion of the Planned Separation of the Consumer Health Business

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions

Bausch + Lomb Corporation (NYSETSX: BLCO) ("Bausch + Lomb") and Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") today announced the closing of the initial public offering ("IPO") of Bausch + Lomb. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") sold 35,000,000 common shares at a public offering price of $18.00 per share for aggregate gross proceeds of $630 million before deducting underwriting commissions and estimated offering expenses. The Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 5,250,000 common shares of Bausch + Lomb to cover over-allotments, if any, at the initial public offering price, less discounts and commissions.

The common shares began trading on the New York Stock Exchange ("NYSE") and the Toronto Stock Exchange ("TSX") on May 6, 2022 , in each case under the ticker symbol "BLCO." Bausch Health, together with its subsidiaries, now holds approximately 90.0% of the common shares of Bausch + Lomb (before giving effect to the over-allotment option).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Bausch Health Companies Inc. Announces First-Quarter 2022 Results

  • First-Quarter 2022 Financial Results
    • Revenues of $1.918 Billion
    • GAAP Net Loss of $69 Million
    • Adjusted EBITDA (non-GAAP) 1 of $732 Million
  • Bausch + Lomb Commences Trading Under "BLCO" Ticker Following IPO 2
  • Updates Full-Year Revenue and Adjusted EBITDA (non-GAAP) 1 Guidance Ranges

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company" or "we") today announced its first-quarter 2022 financial results.

"Our organic 3 growth in the first quarter of 2022 was stable compared to the same quarter last year, despite incremental macro pressures and a challenging supply chain environment," said Thomas J. Appio , incoming chief executive officer ("CEO"), Bausch Health. "Following the closing of the initial public offering of the Bausch + Lomb eye health business later today, we will operate as two companies, which enables Bausch Health to increase its focus on accelerating growth with strategic commercial investments and expanding our pipeline with innovative products that improve the quality of life for patients around the world."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

RNA 9000 Purity and Integrity Kit Allows for Critical High-Resolution Analysis for mRNA Therapeutics

Broad range RNA integrity and quality analysis kit for SCIEX capillary electrophoresis instruments launches at TIDES 2022

At TIDES 2022, SCIEX , a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches the RNA 9000 Purity & Integrity kit, for the BioPhase 8800 system and PA 800 Plus system.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Premier Health of America

Premier Health of America: Modernizing Healthcare Staffing with Automated, On-Demand Services

Premier Health of America (TSXV:PHA) has launched its campaign on the Investing News Network's Medical Device channel.

Premier Health of America (TSXV:PHA) is a modern healthcare staffing platform that gives healthcare workers and facilities access to leading technologies to finally create a truly flexible workforce.

The company’s mobile app technology, PSweb, is at the core of its operations, and the app has been live for over a decade. Artificial intelligence (AI) and big data power the app, delivering a genuinely automated process to healthcare facilities and professionals. The platform serves the healthcare needs of governments, corporations, and individuals. A healthcare facility simply posts an open shift and desired skill set, and providers around the country can claim it.

Keep reading...Show less

Latest Press Releases

Related News

×